Insights into treatment goals and review of the current treatment landscape for lower-risk MDS.
This is a video synopsis/summary of a Precision Medicine series featuring Hana Safah, MD, and Jamie Koprivnikar, MD. Safah and Koprivnikar discuss treatment goals and options for lower-risk patients with myelodysplastic syndrome (MDS) who commonly present with anemia, including up to 40% with severe, transfusion-dependent disease. With median survival of 5 to 6 years, maximizing quality of life is paramount.
Minimum aims are avoiding transfusions and anemia symptoms to allow normal daily activities. Emerging data suggest newer agents like luspatercept may provide further benefits by reducing inflammatory signals and mutational burden.
First-line treatment selection depends on disease features. Lenalidomide is used for MDS with del(5q). Immunosuppressive therapy is chosen for higher erythropoietin levels, whereas erythropoiesis-stimulating agents are utilized when levels are under 500 mU/mL. Luspatercept was initially approved after erythropoiesis-stimulating agent failure but has been expanded as up-front therapy for transfusion-dependent, lower-risk MDS. Achieving transfusion independence may improve overall survival. Ongoing research should uncover more molecularly driven and patient-specific strategies.
Video synopsis is AI generated and reviewed by Targeted Oncology™ editorial staff.
FDA Grants RMAT Designation to TSC-100 and TSC-101 for Hematologic Malignancies
June 1st 2024The FDA granted a regenerative medicine advanced therapy designation to TSC-100 and TSC-101 for hematologic malignancies based on encouraging ALLOHA trial data, offering expedited development and review.
Read More
Antibody-Drug Conjugates Continue to Transform the Oncology Landscape
May 28th 2024In part 1 of our 3-part series, antibody-drug conjugates are revolutionizing oncology, targeting cancer cells precisely. Agents like T-DM1, T-DXd, and sacituzumab govitecan continue to change the field.
Read More